

---

# Contents

---

|              |      |
|--------------|------|
| Preface..... | xvii |
|--------------|------|

## Section I Background

|                                                         |    |
|---------------------------------------------------------|----|
| 1. Quality by Design in Biopharmaceuticals .....        | 3  |
| 1.1 Introduction .....                                  | 3  |
| 1.2 Evolving Regulatory Environment.....                | 4  |
| 1.3 Bioprocess Development.....                         | 6  |
| 1.3.1 Upstream Process .....                            | 7  |
| 1.3.2 Downstream Process.....                           | 8  |
| 1.3.3 Challenges of Bioprocessing .....                 | 8  |
| 1.4 Quality by Design .....                             | 8  |
| 1.4.1 Quality Target Product Profile.....               | 10 |
| 1.4.2 Product and Process Design.....                   | 10 |
| 1.4.2.1 Critical Quality Attributes .....               | 10 |
| 1.4.2.2 Process Development.....                        | 11 |
| 1.4.3 Process Control .....                             | 11 |
| 1.4.4 Contrast between Minimal Approaches and QbD ..... | 13 |
| 1.5 Statistical Opportunities .....                     | 13 |
| 1.5.1 Analytical Method QbD .....                       | 14 |
| 1.5.2 CQAs and Clinical Performance.....                | 15 |
| 1.5.3 Design Space.....                                 | 15 |
| 1.5.4 Control Strategy .....                            | 16 |
| 1.5.5 Continued Improvement .....                       | 17 |
| 1.5.6 Predictive Modeling of Bioprocesses .....         | 17 |
| 1.5.7 Statistical Computing Tools.....                  | 17 |
| 1.5.8 Regulatory Science.....                           | 18 |
| 1.6 New Role of Statisticians .....                     | 18 |
| 1.7 Concluding Remarks .....                            | 19 |

## Section II Analytical Method

|                                       |    |
|---------------------------------------|----|
| 2. Analytical Method Validation ..... | 23 |
| 2.1 Introduction .....                | 23 |
| 2.2 Regulatory Requirements .....     | 24 |
| 2.3 Life Cycle Approach .....         | 25 |
| 2.4 Validation Study Design .....     | 27 |

|           |                                                       |           |
|-----------|-------------------------------------------------------|-----------|
| 2.4.1     | Accuracy and Precision.....                           | 27        |
| 2.4.2     | Experimental Design.....                              | 28        |
| 2.5       | Current Validation Methods.....                       | 30        |
| 2.5.1     | Point Estimate.....                                   | 30        |
| 2.5.2     | Confidence Interval Approach.....                     | 30        |
| 2.5.3     | Total Error Approach .....                            | 33        |
| 2.5.3.1   | "Fit for Purpose" Hypothesis .....                    | 34        |
| 2.5.3.2   | Maximum Likelihood.....                               | 35        |
| 2.5.3.3   | Modified MLE.....                                     | 36        |
| 2.5.3.4   | $\beta$ -Expectation Tolerance Interval .....         | 36        |
| 2.5.3.5   | $\beta$ -Content Tolerance Interval .....             | 38        |
| 2.6       | Generalized Pivotal Quantity Method .....             | 39        |
| 2.6.1     | GPQ of Quality Level .....                            | 40        |
| 2.6.2     | GPQ Test.....                                         | 41        |
| 2.7       | Statistical Test Comparisons.....                     | 41        |
| 2.8       | Other Alternate Methods.....                          | 46        |
| 2.8.1     | Method Based on Capability .....                      | 46        |
| 2.8.2     | Bayesian Approach.....                                | 48        |
| 2.9       | Concluding Remarks .....                              | 50        |
| <b>3.</b> | <b>Parallelism Testing of Bioassay .....</b>          | <b>51</b> |
| 3.1       | Introduction .....                                    | 51        |
| 3.2       | Dose-Response Models .....                            | 52        |
| 3.3       | Parallelism Testing.....                              | 53        |
| 3.3.1     | Measure of Parallelism.....                           | 53        |
| 3.3.2     | Statistical Parallelism Tests.....                    | 56        |
| 3.3.2.1   | Significance Tests.....                               | 56        |
| 3.3.2.2   | Equivalence Tests .....                               | 57        |
| 3.4       | Method Comparison.....                                | 66        |
| 3.4.1     | Measures of Performance .....                         | 67        |
| 3.4.1.1   | Consumer and Producer Risks.....                      | 67        |
| 3.4.1.2   | ROC Curve Analysis.....                               | 69        |
| 3.4.1.3   | Sensitivity versus Specificity .....                  | 71        |
| 3.4.1.4   | Estimation of Sensitivity, Specificity, and AUC ..... | 71        |
| 3.4.1.5   | Simulation .....                                      | 72        |
| 3.4.1.6   | Simulation Results.....                               | 72        |
| 3.5       | Determination of Equivalence Limits.....              | 76        |
| 3.5.1     | Capability-Based Methods .....                        | 76        |
| 3.5.2     | ROC Curve Method.....                                 | 77        |
| 3.5.3     | Limits Based on AUC .....                             | 79        |
| 3.6       | Concluding Remarks .....                              | 80        |
| <b>4.</b> | <b>Validation of Method Linearity.....</b>            | <b>81</b> |
| 4.1       | Introduction.....                                     | 81        |
| 4.2       | Study Design.....                                     | 82        |

|         |                                              |     |
|---------|----------------------------------------------|-----|
| 4.3     | Calibration Model .....                      | 83  |
| 4.4     | Current Statistical Methods.....             | 83  |
| 4.4.1   | Descriptive Summary .....                    | 84  |
| 4.4.1.1 | Visual Inspection.....                       | 84  |
| 4.4.1.2 | Pearson's Correlation Coefficient .....      | 84  |
| 4.4.2   | Significance Tests .....                     | 84  |
| 4.4.2.1 | Lack-of-Fit Test.....                        | 84  |
| 4.4.2.2 | Mendel's Method .....                        | 85  |
| 4.4.2.3 | Kroll's Method .....                         | 85  |
| 4.4.3   | Equivalence Tests .....                      | 86  |
| 4.4.3.1 | Krouwer and Schlain's Method.....            | 87  |
| 4.4.3.2 | Corrected Kroll Method .....                 | 89  |
| 4.4.3.3 | Liu and Hsieh's Methods .....                | 90  |
| 4.4.3.4 | Novick and Yang's Method.....                | 95  |
| 4.5     | Test Linearity on Concentration Scale .....  | 101 |
| 4.5.1   | Extension of Novick and Yang's Method .....  | 101 |
| 4.5.1.1 | Alternative Test.....                        | 102 |
| 4.5.1.2 | Bias on Concentration Scale.....             | 102 |
| 4.5.2   | Statistical Test Methods .....               | 104 |
| 4.5.2.1 | Linear versus Quadratic Models.....          | 104 |
| 4.5.2.2 | Linear versus Higher-Order Polynomials ..... | 105 |
| 4.5.2.3 | Examples.....                                | 107 |
| 4.5.3   | Single-Point Calibration .....               | 109 |
| 4.6     | Concluding Remarks .....                     | 112 |

### Section III Process Development

|         |                                                   |     |
|---------|---------------------------------------------------|-----|
| 5.      | Residual Host Cell DNA Risk Assessment.....       | 115 |
| 5.1     | Introduction .....                                | 115 |
| 5.2     | DNA Inactivation and Removal.....                 | 117 |
| 5.2.1   | Filtration.....                                   | 117 |
| 5.2.2   | DNA Inactivation.....                             | 117 |
| 5.3     | Risk Assessment.....                              | 118 |
| 5.3.1   | Peden, Sheng, and Lewis' Method .....             | 118 |
| 5.3.2   | Krause and Lewis' Method .....                    | 119 |
| 5.3.3   | Yang, Zhang, and Galinski's Method .....          | 119 |
| 5.3.3.1 | Modeling of DNA Inactivation.....                 | 120 |
| 5.3.3.2 | Residual DNA from Oncogenes.....                  | 121 |
| 5.3.3.3 | Safety Factor Estimation.....                     | 122 |
| 5.3.3.4 | Determination of Enzyme Efficiency .....          | 124 |
| 5.3.4   | Safety Factor Estimation Method Comparisons ..... | 126 |
| 5.3.4.1 | Theoretical Results.....                          | 126 |
| 5.3.4.2 | Empirical Comparisons.....                        | 128 |

|         |                                                                |     |
|---------|----------------------------------------------------------------|-----|
| 5.4     | Risk Control .....                                             | 129 |
| 5.4.1   | Specifications Based on Current Standards .....                | 130 |
| 5.4.1.1 | Method .....                                                   | 130 |
| 5.4.1.2 | Example .....                                                  | 131 |
| 5.4.2   | Specifications Based on Acceptable Patient Risk .....          | 133 |
| 5.4.2.1 | Acceptable Ranges .....                                        | 134 |
| 5.4.2.2 | Applications .....                                             | 135 |
| 5.5     | Bayesian Approach .....                                        | 137 |
| 5.5.1   | Posterior Distribution .....                                   | 137 |
| 5.5.2   | Example .....                                                  | 139 |
| 5.6     | Concluding Remarks .....                                       | 140 |
| 6.      | Evaluations of Viral Clearance .....                           | 143 |
| 6.1     | Introduction .....                                             | 143 |
| 6.2     | Viral Clearance Studies .....                                  | 144 |
| 6.2.1   | Choices of Viruses for Viral Clearance Evaluation .....        | 145 |
| 6.2.2   | Selection of Process Steps .....                               | 145 |
| 6.2.3   | Scale-Down of Process Steps .....                              | 145 |
| 6.2.4   | Evaluation of Cytotoxicity and Viral Interference .....        | 146 |
| 6.2.5   | Spiking Experiments and Collection of Process<br>Samples ..... | 146 |
| 6.2.6   | Calculation of Process Capability .....                        | 146 |
| 6.3     | Assays for Viral Quantification .....                          | 147 |
| 6.3.1   | Plaque-Forming Assay .....                                     | 147 |
| 6.3.2   | CPE Assay .....                                                | 148 |
| 6.3.2.1 | Karber Method .....                                            | 149 |
| 6.4     | Virus Titer Estimation for Plaque-Forming Assays .....         | 150 |
| 6.4.1   | Estimation Method Based on Normal Distribution .....           | 150 |
| 6.4.2   | Estimation Method Based on Poisson Distribution .....          | 151 |
| 6.4.2.1 | Maximum Likelihood Estimate .....                              | 152 |
| 6.4.2.2 | Exact Estimate for Poisson Method .....                        | 153 |
| 6.4.2.3 | Poisson Regression .....                                       | 154 |
| 6.5     | Reduction Factor Estimation .....                              | 155 |
| 6.5.1   | Approximate CI .....                                           | 155 |
| 6.5.2   | Exact CI .....                                                 | 156 |
| 6.6     | Comparisons of Estimation Methods .....                        | 157 |
| 6.6.1   | Simulations .....                                              | 157 |
| 6.6.2   | Example .....                                                  | 158 |
| 6.7     | Concluding Remarks .....                                       | 160 |
| 7.      | Bioburden Testing and Control .....                            | 161 |
| 7.1     | Introduction .....                                             | 161 |
| 7.2     | Regulatory Guidelines .....                                    | 163 |
| 7.2.1   | FDA Guidance .....                                             | 164 |

|         |                                                                           |            |
|---------|---------------------------------------------------------------------------|------------|
| 7.2.2   | EMA Perspective.....                                                      | 164        |
| 7.2.3   | Potential Limitations of Regulatory Standards.....                        | 165        |
| 7.3     | Risk-Based Approach.....                                                  | 166        |
| 7.3.1   | Risk Assessment.....                                                      | 167        |
| 7.3.1.1 | Risk Factors.....                                                         | 167        |
| 7.3.1.2 | Criticality Analysis of Risk Factors.....                                 | 169        |
| 7.3.2   | Statistical Risk Analysis.....                                            | 170        |
| 7.3.2.1 | Modeling Prefiltration Bioburden.....                                     | 171        |
| 7.3.2.2 | Performance of Prefiltration Test Procedures ...                          | 174        |
| 7.3.2.3 | Modeling Postfiltration Bioburden.....                                    | 177        |
| 7.3.3   | Risk Control.....                                                         | 179        |
| 7.3.3.1 | First-Tier Risk Factors.....                                              | 179        |
| 7.3.3.2 | Prefiltration Risk Control.....                                           | 180        |
| 7.3.3.3 | Final Postfiltration Risk Control.....                                    | 180        |
| 7.3.3.4 | Control of Second-Tier Risk Factors.....                                  | 182        |
| 7.4     | Applications of Risk-Based Methods.....                                   | 184        |
| 7.4.1   | Justification of Alternative Sample Volumes<br>and Decision Criteria..... | 184        |
| 7.4.2   | Design Space.....                                                         | 185        |
| 7.4.3   | Effects of Risk Factors.....                                              | 187        |
| 7.4.3.1 | EFA and Retention Capability.....                                         | 187        |
| 7.4.3.2 | Effect of Risk Tolerance.....                                             | 189        |
| 7.4.3.3 | Double Filters.....                                                       | 189        |
| 7.5     | Concluding Remarks.....                                                   | 191        |
| 8.      | <b>Process Validation.....</b>                                            | <b>193</b> |
| 8.1     | Introduction.....                                                         | 193        |
| 8.2     | Process Design.....                                                       | 194        |
| 8.2.1   | Identification of CQAs.....                                               | 195        |
| 8.2.1.1 | General Considerations.....                                               | 195        |
| 8.2.1.2 | Example.....                                                              | 195        |
| 8.2.2   | Design Space.....                                                         | 197        |
| 8.2.3   | Statistical Methods for Design Space.....                                 | 197        |
| 8.2.3.1 | Overlapping Mean Response Surfaces.....                                   | 198        |
| 8.2.3.2 | Bayesian Approach.....                                                    | 200        |
| 8.3     | Process Performance Qualification.....                                    | 203        |
| 8.3.1   | Risk-Based Approaches.....                                                | 204        |
| 8.3.1.1 | Determination of Residual Risk Level.....                                 | 204        |
| 8.3.1.2 | Determination of Number of PPQ Batches.....                               | 205        |
| 8.3.2   | Bayesian Alternative.....                                                 | 208        |
| 8.3.2.1 | Generalization of Bayesian Method.....                                    | 211        |
| 8.3.3   | Frequentist Method.....                                                   | 212        |
| 8.3.4   | Method Comparisons.....                                                   | 213        |
| 8.3.4.1 | Numerical Comparison.....                                                 | 213        |

|       |                                     |     |
|-------|-------------------------------------|-----|
| 8.4   | Continued Process Verification..... | 214 |
| 8.4.1 | Multivariate Control Chart.....     | 215 |
| 8.4.2 | Principal Component Analysis.....   | 217 |
| 8.4.3 | PLS Modeling.....                   | 220 |
| 8.5   | Concluding Remarks.....             | 221 |

## Section IV Manufacturing

|          |                                                       |     |
|----------|-------------------------------------------------------|-----|
| 9.       | Specifications.....                                   | 225 |
| 9.1      | Introduction.....                                     | 225 |
| 9.2      | Types of Specifications.....                          | 226 |
| 9.2.1    | Univariate Specifications.....                        | 226 |
| 9.2.2    | Multivariate Specifications.....                      | 227 |
| 9.3      | Specifications for Correlated Quality Attributes..... | 227 |
| 9.3.1    | Linking Specifications to Drug Efficacy.....          | 228 |
| 9.3.2    | Example.....                                          | 230 |
| 9.3.3    | Performance Evaluation.....                           | 233 |
| 9.4      | Specification of Ratio.....                           | 236 |
| 9.4.1    | One-Sided Upper Tolerance Interval.....               | 236 |
| 9.4.2    | Upper Tolerance Limit for $X_1/X_2$ .....             | 237 |
| 9.4.2.1  | Approximate Method.....                               | 237 |
| 9.4.2.2  | Exact Methods.....                                    | 239 |
| 9.4.2.3  | Method Performance.....                               | 240 |
| 9.4.2.4  | Application.....                                      | 241 |
| 9.5      | Release Limits.....                                   | 241 |
| 9.5.1    | Random Batch Model.....                               | 242 |
| 9.5.2    | Estimation of Release Limits.....                     | 243 |
| 9.5.2.1  | Method by Allen et al.....                            | 243 |
| 9.5.2.2  | Wei's Methods.....                                    | 244 |
| 9.5.2.3  | Bayesian Methods.....                                 | 248 |
| 9.6      | Concluding Remarks.....                               | 251 |
| 10.      | Environmental Monitoring.....                         | 253 |
| 10.1     | Introduction.....                                     | 253 |
| 10.2     | Alert and Action Levels.....                          | 254 |
| 10.3     | Statistical Methods.....                              | 254 |
| 10.3.1   | Historical Practice.....                              | 254 |
| 10.3.1.1 | Normal Distribution.....                              | 254 |
| 10.3.1.2 | Nonparameter Intervals.....                           | 255 |
| 10.3.2   | Poisson Distribution.....                             | 256 |
| 10.3.3   | Negative Binomial.....                                | 257 |
| 10.3.3.1 | Direct Approximation.....                             | 257 |
| 10.3.3.2 | Model Comparison.....                                 | 258 |

|            |                                                                         |            |
|------------|-------------------------------------------------------------------------|------------|
| 10.3.4     | Hierarchical Poisson–Gamma Modeling .....                               | 259        |
| 10.3.4.1   | Hierarchical Model .....                                                | 260        |
| 10.3.4.2   | Method Comparison .....                                                 | 262        |
| 10.3.5     | Modeling Excess Zero Counts .....                                       | 263        |
| 10.3.5.1   | Zero-Inflated Models .....                                              | 263        |
| 10.3.5.2   | Parameter Estimation .....                                              | 264        |
| 10.3.5.3   | Alert and Action Limits .....                                           | 265        |
| 10.3.5.4   | Simulation Study .....                                                  | 265        |
| 10.3.6     | Holistic Solution .....                                                 | 266        |
| 10.4       | Trending EM Data .....                                                  | 268        |
| 10.4.1     | Univariate Control Chart .....                                          | 268        |
| 10.4.1.1   | I-MR Charts .....                                                       | 269        |
| 10.4.1.2   | EWMA Control Chart .....                                                | 270        |
| 10.4.2     | Multivariate Control Chart .....                                        | 271        |
| 10.4.2.1   | Bivariate Control Chart .....                                           | 272        |
| 10.4.2.2   | Example .....                                                           | 273        |
| 10.5       | Concluding Remarks .....                                                | 278        |
| <b>11.</b> | <b>Stability Design and Analysis .....</b>                              | <b>279</b> |
| 11.1       | Introduction .....                                                      | 279        |
| 11.2       | Shelf Life Estimation .....                                             | 280        |
| 11.2.1     | Definitions .....                                                       | 280        |
| 11.2.2     | Statistical Models .....                                                | 281        |
| 11.2.3     | Estimation Methods .....                                                | 281        |
| 11.2.3.1   | Confidence Interval Method .....                                        | 283        |
| 11.2.3.2   | Prediction Interval Method .....                                        | 284        |
| 11.2.3.3   | Tolerance Interval Method .....                                         | 284        |
| 11.2.4     | Relationships among Three Methods .....                                 | 284        |
| 11.2.5     | Generalized Confidence Interval Approach<br>to Tolerance Interval ..... | 291        |
| 11.2.6     | Interpretation of Shelf Life Estimates .....                            | 292        |
| 11.2.7     | Shelf Life Estimation Method Comparisons .....                          | 293        |
| 11.2.7.1   | Simulation Study I .....                                                | 294        |
| 11.2.7.2   | Simulation Study II .....                                               | 297        |
| 11.3       | Random-Batch Modeling .....                                             | 298        |
| 11.3.1     | Methods Based on Random Batch .....                                     | 299        |
| 11.3.1.1   | Random-Batch Shelf Life Estimation<br>Method I .....                    | 299        |
| 11.3.1.2   | Random-Batch Shelf Life Estimation<br>Method II .....                   | 300        |
| 11.3.1.3   | Random-Batch Shelf Life Estimation<br>Method III .....                  | 300        |
| 11.3.2     | Random-Batch Shelf Life Estimation Method<br>Evaluations .....          | 301        |
| 11.3.3     | Mixed Model Tolerance Interval .....                                    | 302        |



|            |                                                                            |            |
|------------|----------------------------------------------------------------------------|------------|
| 11.4       | Shelf Life Based on Piecewise Regression.....                              | 303        |
| 11.4.1     | Piecewise Regression Model.....                                            | 304        |
| 11.4.2     | Shelf Life Estimation Using Piecewise Regression.....                      | 306        |
| 11.5       | Other Applications of Stability Studies.....                               | 306        |
| 11.5.1     | Design Space of Storage Temperature.....                                   | 306        |
| 11.5.2     | Evaluation of Stability Design Using Simulation.....                       | 308        |
| 11.5.3     | Bayesian Stability Analysis.....                                           | 311        |
| 11.6       | Concluding Remarks.....                                                    | 312        |
| <b>12.</b> | <b>Investigation of Out-of-Specification and Out-of-Trend Results.....</b> | <b>313</b> |
| 12.1       | Introduction.....                                                          | 313        |
| 12.2       | Background.....                                                            | 313        |
| 12.2.1     | FDA versus Barr Laboratories.....                                          | 313        |
| 12.2.2     | Impacts of Barr Ruling.....                                                | 314        |
| 12.3       | FDA OOS Guidance.....                                                      | 315        |
| 12.3.1     | Phase I Investigation.....                                                 | 315        |
| 12.3.2     | Phase II Investigation.....                                                | 315        |
| 12.3.3     | Phase III Investigation.....                                               | 316        |
| 12.4       | Statistical Methods for OOS Investigation.....                             | 316        |
| 12.4.1     | Graphical Tools.....                                                       | 316        |
| 12.4.1.1   | Boxplot.....                                                               | 316        |
| 12.4.1.2   | Normal Probability (Q-Q) Plot.....                                         | 317        |
| 12.4.2     | Univariate Outlier Tests.....                                              | 319        |
| 12.4.2.1   | Grubb's Test.....                                                          | 319        |
| 12.4.2.2   | Dixon's Test.....                                                          | 319        |
| 12.4.2.3   | Hampel's Test.....                                                         | 320        |
| 12.4.2.4   | Prediction Interval.....                                                   | 320        |
| 12.4.2.5   | Bayesian Method.....                                                       | 321        |
| 12.4.3     | Multivariate Outlier Methods.....                                          | 324        |
| 12.4.4     | Model-Based Methods.....                                                   | 324        |
| 12.4.4.1   | Method Based on Studentized Residuals.....                                 | 324        |
| 12.5       | Retesting and Resampling.....                                              | 326        |
| 12.5.1     | Single-Sampling Plan.....                                                  | 327        |
| 12.5.2     | Double-Sampling Plan.....                                                  | 328        |
| 12.5.3     | Retesting and Resampling Plans.....                                        | 330        |
| 12.6       | Investigation of OOT Results.....                                          | 330        |
| 12.6.1     | Regression Control Chart Method.....                                       | 331        |
| 12.6.2     | By Time Point Method.....                                                  | 332        |
| 12.6.3     | Slope Control Chart Method.....                                            | 332        |
| 12.7       | Concluding Remarks.....                                                    | 332        |
|            | <b>References.....</b>                                                     | <b>335</b> |
|            | <b>Index.....</b>                                                          | <b>349</b> |